Table 4.
Results of the logistic regression models on the risk of hospital/ED associated CINV events
|
Parameter |
Breast cancer (N = 3606) |
Carboplatin-treated Lung cancer (N = 4497) |
Cisplatin-treated lung cancer (N = 1154) |
|||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| age |
NS |
NS |
NS |
NS |
NS |
NS |
| CCI |
1.247 (1.122-1.387) |
<.0001 |
1.042 (1.012-1.073) |
0.0052 |
NS |
NS |
| Gender (male as reference) | ||||||
| Female |
NA |
NA |
0.817 (0.678-0.985) |
0.0338 |
NS |
NS |
| Days with cyclophosphamide (in breast cancer) or carboplatin or cisplatin (in lung cancer) treatment |
0.719 (0.619-0.836) |
<.0001 |
0.942 (0.915-0.969) |
<.0001 |
NS |
NS |
| Antiemetic regimen (older 5-HT3 RAs as reference) | ||||||
| Palonosetron | 0.618 (0.447-0.854) | 0.0035 | 0.712 (0.586-0.864) | 0.0006 | 0.707 (0.514-0.972) | 0.0330 |
NA: not applicable, NS: Not significant.